Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85289 | 0.88 | MAPT (0.38) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL85472 | 0.86 | MAPT (0.37) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL85286 | 0.85 | MAPT (0.36) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL85517 | 0.82 | ALDH1A1 (0.43) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13698585 | 0.81 | MAPT (0.33) | MAPTALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3021911 | 0.75 | MAPT (0.46) | MAPTALDH1A1MEN1KMT2APOLB | |
| SCHEMBL2341968 | 0.74 | MAPT (0.51) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL2341343 | 0.74 | MAPT (0.51) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL2345801 | 0.74 | MAPT (0.51) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL2341347 | 0.74 | MAPT (0.51) | MAPTALDH1A1MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | MAPT 4773/4885ALDH1A1 207/4885SMN1; SMN2 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.